Nedosiran
As of the edition of 20 October 2026, Nedosiran is an oligonucleotide: marketed, first approved in 2023 (US); acts on ASGR1, ASGR2 and LDHA; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Oligonucleotide
- Brand name
- Rivfloza
- First approved
- 29 September 2023 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Novo Nordisk
- Registered trials
- 2, 0 stopped early
- Disease areas
- Inherited and neonatal; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Nedosiran.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novo Nordisk | Originator and Lead sponsor of trials | 2023 to now |